Midazolam microdosing applied in early clinical development for drug-drug interaction assessment
Aims We aimed to incorporate a pharmacologically inactive midazolam microdose into early clinical studies for the assessment of CYP3A drug-drug interaction liability. Methods Three early clinical studies were conducted with substances (Compounds A, B and C) which gave positive CYP3A perpetrator sign...
Gespeichert in:
| Hauptverfasser: | , , , , , , , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
2021
|
| In: |
British journal of clinical pharmacology
Year: 2020, Jahrgang: 87, Heft: 1, Pages: 178-188 |
| ISSN: | 1365-2125 |
| DOI: | https://doi.org/10.1111/bcp.14389 |
| Online-Zugang: | Verlag, kostenfrei, Volltext: https://doi.org/https://doi.org/10.1111/bcp.14389 Verlag, kostenfrei, Volltext: https://bpspubs.onlinelibrary.wiley.com/doi/abs/10.1111/bcp.14389 
|
| Verfasserangaben: | Sabrina T. Wiebe, Andreas Huennemeyer, Werner Kadus, Markus Goettel, Alen Jambrecina, Armin Schultz, Richard Vinisko, Laura Schlieker, Lena Herich, Gerd Mikus |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1755326122 | ||
| 003 | DE-627 | ||
| 005 | 20230427042526.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 210419r20212020xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1111/bcp.14389 |2 doi | |
| 035 | |a (DE-627)1755326122 | ||
| 035 | |a (DE-599)KXP1755326122 | ||
| 035 | |a (OCoLC)1341404408 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Wiebe, Sabrina |e VerfasserIn |0 (DE-588)1219325988 |0 (DE-627)1735273597 |4 aut | |
| 245 | 1 | 0 | |a Midazolam microdosing applied in early clinical development for drug-drug interaction assessment |c Sabrina T. Wiebe, Andreas Huennemeyer, Werner Kadus, Markus Goettel, Alen Jambrecina, Armin Schultz, Richard Vinisko, Laura Schlieker, Lena Herich, Gerd Mikus |
| 264 | 1 | |c 2021 | |
| 300 | |a 11 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a First published: 20 May 2020 | ||
| 500 | |a Gesehen am 19.04.2021 | ||
| 520 | |a Aims We aimed to incorporate a pharmacologically inactive midazolam microdose into early clinical studies for the assessment of CYP3A drug-drug interaction liability. Methods Three early clinical studies were conducted with substances (Compounds A, B and C) which gave positive CYP3A perpetrator signals in vitro. A 75 μg dose of midazolam was administered alone (baseline CYP3A activity) followed by administration with the highest dose groups tested for each compound on Day 1/3 and Day 14 or Day 17. Midazolam exposure (AUC0-∞, Cmax) during administration with the test substances was compared to baseline data via an analysis of variance on log-transformed data. Partial AUC2-4 ratios were also compared to AUC0-∞ ratios using linear regression on log-transformed data. Results Test compound Cmax values exceeded relevant thresholds for drug-drug interaction liability. Midazolam concentrations were quantifiable over the full profiles for all subjects in all studies. Point estimates of the midazolam AUC0-∞ gMean ratios ranged from 108.3 to 127.1% for Compound A, from 93.3 to 114.5% for Compound B, and from 92.0 to 96.7% for the two highest dose groups of Compound C. Cmax gMean ratios were in the same range. Thus, no relevant drug-drug interactions were evident, based on the results of midazolam microdosing. AUC2-4 ratios from these studies were comparable to the AUC0-∞ ratios. Conclusion Midazolam microdosing incorporated into early clinical studies is a feasible tool for reducing dedicated drug-drug interaction studies, meaning reduced subject burden. Limited sampling could further reduce subject burden, costs and needed resources. | ||
| 534 | |c 2020 | ||
| 650 | 4 | |a CYP3A | |
| 650 | 4 | |a drug-drug interactions | |
| 650 | 4 | |a early clinical development | |
| 650 | 4 | |a microdosing | |
| 650 | 4 | |a midazolam | |
| 700 | 1 | |a Huennemeyer, Andreas |e VerfasserIn |4 aut | |
| 700 | 1 | |a Kadus, Werner Uli |d 1959- |e VerfasserIn |0 (DE-588)11548423X |0 (DE-627)691353441 |0 (DE-576)289908906 |4 aut | |
| 700 | 1 | |a Goettel, Markus |e VerfasserIn |4 aut | |
| 700 | 1 | |a Jambrecina, Alen |d 1971- |e VerfasserIn |0 (DE-588)128871873 |0 (DE-627)383671310 |0 (DE-576)297374044 |4 aut | |
| 700 | 1 | |a Schultz, Armin |d 1956- |e VerfasserIn |0 (DE-588)133444155 |0 (DE-627)691452504 |0 (DE-576)299852474 |4 aut | |
| 700 | 1 | |a Vinisko, Richard |e VerfasserIn |4 aut | |
| 700 | 1 | |a Schlieker, Laura |e VerfasserIn |4 aut | |
| 700 | 1 | |a Herich, Lena |e VerfasserIn |4 aut | |
| 700 | 1 | |a Mikus, Gerd |e VerfasserIn |0 (DE-588)110903137 |0 (DE-627)691097941 |0 (DE-576)336988710 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t British journal of clinical pharmacology |d Oxford : Wiley-Blackwell, 1974 |g 87(2021), 1, Seite 178-188 |h Online-Ressource |w (DE-627)306585995 |w (DE-600)1498142-7 |w (DE-576)091140056 |x 1365-2125 |7 nnas |a Midazolam microdosing applied in early clinical development for drug-drug interaction assessment |
| 773 | 1 | 8 | |g volume:87 |g year:2021 |g number:1 |g pages:178-188 |g extent:11 |a Midazolam microdosing applied in early clinical development for drug-drug interaction assessment |
| 856 | 4 | 0 | |u https://doi.org/https://doi.org/10.1111/bcp.14389 |x Verlag |x Resolving-System |z kostenfrei |3 Volltext |
| 856 | 4 | 0 | |u https://bpspubs.onlinelibrary.wiley.com/doi/abs/10.1111/bcp.14389 |x Verlag |z kostenfrei |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20210419 | ||
| 993 | |a Article | ||
| 994 | |a 2021 | ||
| 998 | |g 110903137 |a Mikus, Gerd |m 110903137:Mikus, Gerd |d 910000 |d 910100 |d 50000 |e 910000PM110903137 |e 910100PM110903137 |e 50000PM110903137 |k 0/910000/ |k 1/910000/910100/ |k 0/50000/ |p 10 |y j | ||
| 998 | |g 1219325988 |a Wiebe, Sabrina |m 1219325988:Wiebe, Sabrina |d 50000 |e 50000PW1219325988 |k 0/50000/ |p 1 |x j | ||
| 999 | |a KXP-PPN1755326122 |e 3913280340 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"type":{"bibl":"article-journal","media":"Online-Ressource"},"note":["First published: 20 May 2020","Gesehen am 19.04.2021"],"recId":"1755326122","language":["eng"],"person":[{"role":"aut","roleDisplay":"VerfasserIn","display":"Wiebe, Sabrina","given":"Sabrina","family":"Wiebe"},{"family":"Huennemeyer","given":"Andreas","roleDisplay":"VerfasserIn","display":"Huennemeyer, Andreas","role":"aut"},{"display":"Kadus, Werner Uli","roleDisplay":"VerfasserIn","role":"aut","family":"Kadus","given":"Werner Uli"},{"role":"aut","display":"Goettel, Markus","roleDisplay":"VerfasserIn","given":"Markus","family":"Goettel"},{"roleDisplay":"VerfasserIn","display":"Jambrecina, Alen","role":"aut","family":"Jambrecina","given":"Alen"},{"given":"Armin","family":"Schultz","role":"aut","roleDisplay":"VerfasserIn","display":"Schultz, Armin"},{"given":"Richard","family":"Vinisko","role":"aut","display":"Vinisko, Richard","roleDisplay":"VerfasserIn"},{"family":"Schlieker","given":"Laura","roleDisplay":"VerfasserIn","display":"Schlieker, Laura","role":"aut"},{"display":"Herich, Lena","roleDisplay":"VerfasserIn","role":"aut","family":"Herich","given":"Lena"},{"role":"aut","display":"Mikus, Gerd","roleDisplay":"VerfasserIn","given":"Gerd","family":"Mikus"}],"title":[{"title":"Midazolam microdosing applied in early clinical development for drug-drug interaction assessment","title_sort":"Midazolam microdosing applied in early clinical development for drug-drug interaction assessment"}],"physDesc":[{"extent":"11 S."}],"relHost":[{"pubHistory":["1.1974 -"],"titleAlt":[{"title":"BJCP"}],"part":{"issue":"1","pages":"178-188","year":"2021","extent":"11","volume":"87","text":"87(2021), 1, Seite 178-188"},"note":["Gesehen am 20.03.2014"],"disp":"Midazolam microdosing applied in early clinical development for drug-drug interaction assessmentBritish journal of clinical pharmacology","type":{"media":"Online-Ressource","bibl":"periodical"},"recId":"306585995","language":["eng"],"title":[{"title_sort":"British journal of clinical pharmacology","title":"British journal of clinical pharmacology","subtitle":"BJCP"}],"physDesc":[{"extent":"Online-Ressource"}],"origin":[{"dateIssuedDisp":"1974-","publisher":"Wiley-Blackwell ; Blackwell Science ; Blackwell","dateIssuedKey":"1974","publisherPlace":"Oxford ; Oxford ; Oxford [u.a.]"}],"id":{"issn":["1365-2125"],"zdb":["1498142-7"],"eki":["306585995"],"doi":["10.1111/(ISSN)1365-2125"]}}],"name":{"displayForm":["Sabrina T. Wiebe, Andreas Huennemeyer, Werner Kadus, Markus Goettel, Alen Jambrecina, Armin Schultz, Richard Vinisko, Laura Schlieker, Lena Herich, Gerd Mikus"]},"origin":[{"dateIssuedKey":"2021","dateIssuedDisp":"2021"}],"id":{"doi":["10.1111/bcp.14389"],"eki":["1755326122"]}} | ||
| SRT | |a WIEBESABRIMIDAZOLAMM2021 | ||